** Drug developer Viking Therapeutics VKTX.O late on Wednesday reported a wider second-quarter net loss of $65.6 million, and said it expects to report mid-stage trial results of its oral obesity drug in the second half of the year
** Shares of the company were down 8.2% at $30.65 premarket
ALL EYES ON OBESITY DRUG CANDIDATE VK2735
** H.C.Wainwright ("buy") says as Viking progresses through 2025, the VK2735 clinical program remains on a strong trajectory. "We continue to believe VK2735 is well-positioned within the GLP-1 landscape, across both subcutaneous and oral formulations"
** Co is testing its obesity drug candidate, VK2735, in both oral and under-the-skin formulations in mid-stage and late-stage studies
** William Blair ("outperform") says given the unprecedented market opportunity in obesity, it believes the value of VK2735 will ultimately be maximized in the hands of a big pharma company
** BTIG ("buy," PT: $125) says "overall, we continue to see VKTX remaining at the front of the pack in the obesity race with meaningful upside to shares headed into 2H25"
** Truist Securities ("buy," PT: $75) says "we expect rich dataset to emerge out of monthly dosing study that may help set VK2735 franchise for commercial success"
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.